Molecular Partners: 1st Patient Dosed in a Phase 2 Trial of Ensovibep in COVID-19

 

• First Study of Ensovibep in Patients With Symptomatic COVID-19 Disease
• Designed To Evaluate Dynamics of Viral Clearance, Pharmacokinetics and Tolerability of Ensovibep
• Ensovibep Is Additionally Planned To Be Tested in Two Global, Placebo Controlled, Double Blinded Trials: A Phase 2–3 Trial in an Ambulatory Patient Setting (Named EMPATHY), and a Phase 3 Trial in a Hospitalized Patient Setting Sponsored by the NIH (ACTIV-3)

https://www.biospace.com/article/releases/molecular-partners-announces-first-patient-dosed-in-a-phase-2-clinical-trial-of-ensovibep-in-covid-19-patients/